As Vertex Pharmaceuticals INC (VRTX) Shares Rose, Guggenheim Capital LLC Decreased Stake by $79.96 Million

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Corporate LogoBig Money Sentiment increased to 1.3 in Q2 2018. It has change of 0.15, from 2018Q1’s 1.15. The ratio is positive due to VRTX positioning: 34 sold and 176 reduced. 61 funds bought positions and 211 increased positions. Investors holded 232.72 million in 2018Q1 but now own 236.55 million shares or 1.64% more. Virginia Retirement Systems Et Al reported 3,500 shs. Guardian Life Insurance Communication Of America holds 0.02% of its capital in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 700 shs. State Of New Jersey Common Pension Fund D reported 0.15% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Bp Public Limited Co, United Kingdom-based fund reported 30,000 shs. Lucas Capital Management has 0.33% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Moreover, Sandy Spring Comml Bank has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 300 shs. Cullinan Assocs has 120,342 shs for 1.56% of their capital. Salem Invest Counselors stated it has 0.03% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 1.10 million were accumulated by D E Shaw Communication. Baystate Wealth Mngmt Limited Liability Com has 110 shs. Pura Vida has invested 2.16% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Exane Derivatives holds 709 shs. Ls Inv Lc invested in 8,212 shs or 0.08% of the stock. Goldman Sachs Gru holds 0.15% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 3.35M shs. Trexquant LP has invested 0.35% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

VRTX had 19 insider sales and 0 buys since May 15, 2018. This’s net activity of $37.73 million. ALTSHULER DAVID sold 23,375 shs worth $4.25 million. On Thursday, July 5 Parini Michael also sold $715,615 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). LEIDEN JEFFREY M sold $22.43M worth of stock or 140,211 shs. $492,385 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Silva Paul M. 4,250 shs valued at $675,750 were sold by Arbuckle Stuart A on Friday, June 22. On Friday, July 13 the insider Sachdev Amit sold $2.48M.

Based on the latest 2018Q2 regulatory filing with the SEC, Guggenheim Capital Llc reduced its holdings in Vertex Pharmaceuticals Inc (VRTX) by 64.3%. The company’s stock popped up 17.38% while Guggenheim Capital Llc sold 473,152 shares. At the end of 2018Q2, the 262,697 shares of the major pharmaceuticals company held by the institutional investor were priced at $44.65M, down from 735,849 at the end of the previous reported quarter. Vertex Pharmaceuticals Inc has $46.14 billion MC. VRTX reached $180.55 during the last trading session after $0.29 change.Vertex Pharmaceuticals Incorporated is uptrending after having risen 13.72% since November 10, 2017. VRTX has 1.85M volume or 48.19% up from normal. The stock underperformed the S&P500 by 1.90%.

According to a filing Guggenheim Capital Llc increased its stake in First Horizon Natl Corp (NYSE:FHN) by 350,490 shares to 456,939 shares, valued at $8.15 million in 2018Q2. The fund operates about $25.60 billion and $14.98B US Long portfolio. Guggenheim Capital Llc has risen its stake in Exelixis Inc (NASDAQ:EXEL) and also increased its holding in Herbalife Nutrition Ltd (NYSE:HLF) by 63,992 shares in the quarter, for a total of 91,264 shares.

For more Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news published recently go to: Seekingalpha.com, Fool.com, Bizjournals.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Vertex Pharmaceuticals beats by $0.07, misses on revenue” published on October 24, 2018, “Vertex Pharmaceuticals Waits to Hit the Triple” on October 29, 2018, “Cambridge’s Editas asks FDA to start gene editing trial” with a publish date: November 08, 2018, “Vertex Q3 revenues up 36%; earnings up 225%” and the last “10 Strong Buy Stocks Trading at Killer Entry Points” with publication date: November 08, 2018.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Total analysts of 7 have positions in Vertex Pharmaceuticals (NASDAQ:VRTX) as follows: 6 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 86%. Since July 26, 2018 according to StockzIntelligence Inc Vertex Pharmaceuticals has 7 analyst reports. On Monday, July 30 Citigroup maintained the shares of VRTX in report with “Buy” rating. On Thursday, October 25 the stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Outperform” rating by Raymond James. On Thursday, July 26 the rating was maintained by Morgan Stanley with “Overweight”. On Thursday, October 25 the stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Outperform” rating by BMO Capital Markets. On Friday, October 26 the stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by H.C. Wainwright. On Thursday, July 26 the rating was maintained by UBS with “Neutral”.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.